StreetAlpha.app
Home › Stocks › ARE

Alexandria Real Estate Equities, Inc. (ARE)

Real Estate
$42.39
▼ −2.66%
LAST CLOSE · NOV 17

Alexandria Real Estate Equities owns, operates, and develops life science properties and campuses for science-focused tenants. It last closed at $42.39 on Nov 17, down 2.66% on the day. ARE reports earnings on Mon, Jan 25, 2027. The average 12-month price target from 6 analysts is $47.33 (+11.7% from the last close), with a high of $56.00 and a low of $37.00. Analyst consensus is Hold, based on the latest ratings from 6 firms (1 buy, 3 hold, 2 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in ARE, 0% of them bullish and 100% bearish.

AI Auto Pilots
Is ARE in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$2.8B
−9.9% vs a year ago
Net income
−$1.4B
−51.8% margin
EPS (diluted)
−$8.41
Valuation
Market cap
$7.4B
174.2M shares
P/E
–
No P/E while losing money
Price to sales
2.7
Market cap over revenue
Dividend yield
6.79%
$2.88 a share over 12 months
Balance sheet
Cash & equivalents
$508.9M
At Sep 30
Debt
$12.9B
At Sep 30
Shareholder equity
$14.8B
Shares outstanding
174.2M
At Oct 15
CEOPeter M. Moglia
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $2.1B$2.1BFY2021FY2022: $2.6B$2.6BFY2022FY2023: $2.9B$2.9BFY2023FY2024: $3.1B$3.1BFY2024FY2025: $3.0B$3.0BFY2025

From ARE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 26). Last 12 months adds up the four latest quarters.

Next report
Jan 25
2027 · Time not announced
Consensus EPS forecast
-$0.02
$645.0M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Hold
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Hold
6firms
1 Buy3 Hold2 Sell
Each firm's latest rating on ARE in the past 90 days
Average 12-month target
$47.33
▲ 11.7% upside

Based on 6 analysts who set a price target on ARE in the past 90 days. The average target is $47.33, with a high of $56.00 and a low of $37.00, compared with the last close of $42.39.

Low $37.00Avg $47.33High $56.00
Blue marker: last close $42.39
Highest target$56.00
Average target$47.33
Lowest target$37.00
Latest rating changes
MizuhoTarget lowered
Nov 16Buy$60 → $50
RBC CapitalMaintained
Nov 3Hold$47
Cantor FitzgeraldTarget lowered
Oct 28Hold$52 → $42
BNP ParibasTarget lowered
Oct 28Sell$48 → $37
JP MorganDowngrade
Sep 24Sell$56
DateFirmActionRatingPrice target
Nov 16MizuhoTarget loweredBuy$60 → $50
Nov 3RBC CapitalMaintainedHold$47
Oct 28Cantor FitzgeraldTarget loweredHold$52 → $42
Oct 28BNP ParibasTarget loweredSell$48 → $37
Sep 24JP MorganDowngradeSell$56
Loading…

Technical Analysis

ARE · as of the Nov 17 close · updated after every close
Downtrend

The stock is 2% below its 20 day and 9% below its 50 day average. It is 15% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 43). The nearest support is the Pivot S1 at $41.84, and the nearest resistance the Pivot at $42.56.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 4.2%/day
Key levels
$59.7652 week high+41.0%
$48.79200 day average+15.1%
$48.40100 day average+14.2%
$46.1350 day average+8.8%
$43.91Swing high (Oct 22)+3.6%
$43.2120 day average+1.9%
$43.11Pivot R1+1.7%
$42.56Pivot+0.4%
$42.39Last close
$41.84Pivot S1−1.3%
$39.95Swing low (Oct 19)−5.8%
$38.3452 week low−9.6%
Indicators
RSI (14)42.90Middle of its rangeNeutral
MACD-0.37Above its signal lineBullish
Stochastic48.8Middle of its rangeNeutral
ADX (14)20.9Weak trend
Williams %R-66.3Oversold below −80, overbought above −20Neutral
CCI (20)-26.8Oversold below −100, overbought above 100Neutral
Rate of change+0.3%Change over 10 sessionsBullish
ATR (14)$1.77Typical daily range, 4.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ARE

What happened before

See how ARE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ARE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ARE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
0
0%
Bearish
1
100%
Date span
Aug 20 – Aug 20
Loading…

See today’s whale options flow across the market →

ARE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▲314 buying vs 256 selling
  • ▼Held by funds -10.8 pts
  • ▼Funds holding -11
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding588599−1.8%
In funds' top 1034−25.0%
Held by funds86.7%97.5%−10.8 pts
New / increased72 / 242103 / 230−5.7%
Reduced / sold out186 / 70192 / 74−3.8%
Put/call ratio0.711.09−35.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ARE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ARE Stock Buybacks

See all S&P 500 buybacks →
Spent, 12 months
$0
0.0% yield
Left in program
$500.0M
6.8% of value
Shares outstanding, 12 months
+0.8%
More shares
Last quarter
—
Sep 2026
Avg price paid, last quarter
—
 
S&P 500 rank by spending
—
 
Spent each quarter, last 3 yearsTop bar $208.1M
Dec 2023: $0Mar 2024: $0Jun 2024: $0Sep 2024: $0Dec 2024: $50.1M, average price $100.95Mar 2025: $208.1M, average price $96.71Jun 2025: $0Sep 2025: $0Dec 2025: $0, average price $96.71Mar 2026: $0Jun 2026: $0Sep 2026: $0
Dec 2023Sep 2026
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.

From the company's 10-Q filed Oct 26, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARE is in one of them and how their past ARE trades turned out.

ARE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ARE in an article yet. Here's the latest on the wider market.

ARE Congress Trades

All congress trades →
Trades, 12 months
21
Buys
12
57%
Sells
9
43%
People
4
Last filed Nov 10
Who traded ARE · since 2014
Latest 5 filings of 85
$1K – $15KTraded Oct 20, 2026Filed Nov 10, 2026
$1K – $15KTraded Oct 7, 2026Filed Nov 9, 2026
$1K – $15KTraded Sep 25, 2026Filed Oct 7, 2026
$1K – $15KTraded Sep 11, 2026Filed Oct 7, 2026
$1K – $15KTraded May 22, 2026Filed Jul 1, 2026
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KOct 20, 2026Nov 10, 202621 d
Ro KhannaD · CASell$1K – $15KOct 7, 2026Nov 9, 202633 d
Ro KhannaD · CABuy$1K – $15KSep 25, 2026Oct 7, 202612 d
Ro KhannaD · CABuy$1K – $15KSep 11, 2026Oct 7, 202626 d
Donald J TrumpExecutive branchSell$1K – $15KMay 22, 2026Jul 1, 202640 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Alexandria Real Estate Equities

Alexandria Real Estate Equities is a real estate investment trust that owns, operates, and develops life science properties and campuses in North America. Its properties are clustered in major life science hubs, including Greater Boston, the San Francisco Bay Area, and San Diego. Tenants include pharmaceutical and biotechnology companies, medical device makers, academic and medical research institutions, and U.S. government research agencies. The company is based in Pasadena, California.

Headquarters
Pasadena, CA
Founded
1994